Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News

Back a little over 5 years ago, I reported on a major disaster for Exelixis $EXEL when cabozantinib flopped in a comparison with prednisone in treating castration-resistant prostate cancer. Caught between a rock and a hard place, the company immediately whacked 70% of its work force, as new CEO Michael Morrissey steered away from the rocks with what was left of the crew.

Morrissey and the survivors took a conservative course, hanging on to get an OK for the TKI, which ultimately proved a fairly effective market maker as Cabometyx, with more than $1 billion in total revenue over a 4-quarter stretch. And at JP Morgan a few weeks ago Morrissey threw his customary caution to the wind, painting a rosy picture of the future, with a potential to make the company into a $4 billion earner by 2025, with 3 upcoming pivotal readouts.

Unlock this story instantly and join 71,900+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See original here:
Merck-allied Seattle Genetics' positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line - Endpoints News

BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response – Reuters

Feb 11 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM PHASE 1B/2 TRIAL OF PADCEV (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS INVESTIGATIONAL FIRST-LINE TREATMENT FOR ADVANCED BLADDER CANCER

* SEATTLE GENETICS - AFTER MEDIAN FOLLOW-UP OF 11.5 MONTHS, 73% OF PATIENTS HAD CONFIRMED TUMOR RESPONSE WITH MAJORITY OF RESPONSES STILL ONGOING

* SEATTLE GENETICS INC - NO NEW SAFETY SIGNALS OBSERVED FOR COMBINATION Source text for Eikon: Further company coverage:

More:
BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response - Reuters

Government considers storage limit extension for frozen eggs, sperm and embryos – The Argus

The limit on how long frozen eggs, sperm and embryos can be stored may be extended amid concerns women are being disproportionately affected, the Government has announced.

Currently, the storage period is a maximum of 10 years, after which families must decide whether to undergo fertility treatment or have their eggs, sperm and embryos destroyed.

The Department of Health and Social Care is asking people whether they feel this should be changed amid fears that the 10 year limit disproportionately affects women who want to freeze their eggs.

The number of women freezing their eggs has soared by 257% since 2012, with 1,462 egg freezing cycles in 2017 compared to 410 in 2012, while freezing technologies have become more advanced.

Only those stored for medical reasons, such as cancer treatment, and premature infertility can be preserved for longer up to 55 years in total.

Both men and women may freeze their sperm and/or eggs for non-medical reasons, such as wanting to have children in future but not having a partner.

The Government is launching a public consultation into whether the limit should be changed.

Minister for Care Caroline Dinenage said: Every person should be given the best possible opportunity to start a family, which is why it is so important that our laws reflect the latest in technological advancements.

Although this could affect any one of us, I am particularly concerned by the impact of the current law on womens reproductive choices.

A time limit can often mean women are faced with the heart-breaking decision to destroy their frozen eggs, or feel pressured to have a child before they are ready.

As the number of people seeking this storage rises, we want to hear from the public about whether the law is fair and proportionate, and ensure everyone is empowered to choose when they become parents.

A woman has a better chance of a healthy pregnancy if she freezes her eggs in her 20s when her fertility is at its peak.

However, the current 10-year limit would then expire in her 30s, which may be too early for some women to start a family.

The most common age for women to freeze their eggs is currently 38.

The Government will also consider issues of safety and quality, and additional demand for storage facilities, should the limit be extended.

Sally Cheshire, chairwoman of the Human Fertilisation and Embryology Authority, said: As the fertility regulator we have heard the voices of patients and clinicians calling for a review and extension of the current time limit for egg, embryo and sperm storage.

While any change to the 10-year storage limit would be a matter for Parliament as it requires a change in law, we believe the time is right to consider what a more appropriate storage limit could be that recognises both changes in science and in the way women are considering their fertility.

Go here to see the original:
Government considers storage limit extension for frozen eggs, sperm and embryos - The Argus

INmune Bio, Inc. Awarded $500000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS – BioSpace

Grant will fund proof-of-concept studies for XPro1595 therapy

LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmuneBio, Inc. (NASDAQ: INMB), an immunology company developing treatments that reprogram the patients innate immune system to fight disease, today announced that it has been awarded a $500,000 grant from The ALS Association. The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis (ALS). The endowment was awarded through the Associations The Lawrence and Isabel Barnett Drug Development Program and will be allocated over two years.

We are honored to receive this grant from The ALS Association, the pre-eminent organization supporting novel treatments for ALS, said R.J. Tesi, M.D., Chief Executive Officer of INmune Bio. As an immunology company, we focus on the role that innate immune dysfunction and neuroinflammation play in the progression of neurodegenerative diseases such as ALS. This award supports our approach and moves the companys ALS program closer to the clinic.

While our knowledge of ALS has increased dramatically in the past few years, there are currently no disease modifying therapies, said CJ Barnum, Ph.D., Director of Neuroscience for INmune Bio. The innate immune system plays a central role in the development and progression of ALS. We believe precision targeting of the innate immune system by targetinginflammationwith XPro1595may be an effective treatment strategy inalleviating ALS. This award allows INmune Bio to take the first step to determine whether XPro1595 has therapeutic potential for ALS patients.

We believe INmune is on a path to unlocking some of the mystery around the immune system and how it responds to the kinds of inflammation that we know plays a role in ALS progression, said Kuldip Dave, Ph.D, vice president of research at The ALS Association. This grant will greatly accelerate proof of concept and advance our knowledge of immune dysfunction and neuroinflammation in people living with ALS.

About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patients innate immune systems response to their disease - immune priming platform and DN-TNF platform. The immune priming platform is a Natural Killer (NK) cell therapeutic that primes the patients NK cells to attack residual disease the cause of cancer relapse. The DN-TNF platform includes programs in cancer, neurodegenerative disease and NASH. INB03 modifies the tumor microenvironment which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors and trastuzumab. XPro1595 targets microglial activation, nerve cell death and synaptic dysfunction associated with neurodegenerative disease. LivNate modifies metabolic and immunologic pathology that contributes to the development and progression of NASH. To learn more, please visit http://www.inmunebio.com.

About The ALS AssociationThe ALS Association is the largest private funder of ALS research in the world. The Association funds global research collaborations, provides assistance for people with ALS and their families through its nationwide network of chapters and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure. For more information about The ALS Association, visit our website at http://www.alsa.org. For more information about The Lawrence and Isabel Barnett Drug Development Program, please visit: http://www.alsa.org/research/our-approach/call-for-abstracts/barnett-drug-development-request-for-proposals-081619.html

Forward-Looking Statements

There is no guarantee that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3, LivNate, INKmune and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K for the year ended December 31, 2018, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact: David Moss, CFO(858) 964-3720DMoss@INmuneBio.com

The ALS Association Contact:Brian Frederick,Ph.D. Executive Vice President, Communications(202) 464-8612bfrederick@alsa-national.org

Media Contact:David Schull(212) 845-4271David.Schull@russopartnersllc.com

Investor Contact:James CarbonaraHayden IR(646)-755-7412james@haydenir.com

More:
INmune Bio, Inc. Awarded $500000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS - BioSpace

‘We’re responding to this threat’: University of Alberta works to help stop novel coronavirus – Edmonton Journal

The University of Albertas Li Ka Shing Institute of Virology says a drug once used in an Ebola outbreak could fight the novel coronavirus.

Remdesivir will be tested against the virus, known as 2019-nCoV, at the institute in Edmonton. Although there are regulatory hurdles related to getting samples of the coronavirus into the country, lab work has already begun, said Dr. Lorne Tyrrell, founding director of the Li Ka Shing Institute of Virology.

The prospects for developing an antivirus that can be used in patients is very good, and it may happen in the next few weeks and be readily available some compounds that are already on the market for their viruses that might work (against) this virus, said Tyrrell.

The institute is aiming to raise up to half a million dollars in funding, including rapid response grants from the Canadian Institute of Health Research, to go towards work on the novel coronavirus, Tyrrell said.

No one at the institute specializes in coronavirus at the moment. That is going to change very quickly, said Tom Hobman, professor of medical microbiology and immunology at the university, who noted that experts on coronaviruses have been recruited.

Since it can take years to get a brand new drug to market, researchers at the institute hope to find a drug thats already been developed to fight the virus.

Remdesivir, one of the drugs they will test, was used in the emergency treatment of patients with Ebola virus infection in the Democratic Republic of the Congo. The drug has shown activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to the novel coronavirus, and has been used on a small number of patients.

Since the outbreak of the new coronavirus, it was just logical to ask whether this drug will work against the new coronavirus. The good thing was that its been tested, with tons of pre-clinical data, as well as in very difficult clinical settings, said Matthias Gtte, chair of the department of medical microbiology and immunology.

We are interested, always, not in the entire virus, but in the little machines the enzymes that help the virus to propagate. As soon as you shut down the machine, you shut down the virus, and you have a drug, said Gtte. Now, the goal is to see if the mechanism works the same way against the novel coronavirus.

If youre trying to respond very quickly to an outbreak, you dont really have the luxury of time to develop something completely new, said Dave Evans, professor of medical microbiology and immunology.

The challenge with all drug development is making sure it works and is safe, so its a common approach to test drugs that are known to be safe on new viruses, said Evans.

Viruses change, and new viruses are always emerging, said Tyrrell.

Public health efforts to contain the novel coronavirus have been more challenging than in other outbreaks, including SARS, but the mortality rate is so far much lower, he said. There have been at least 40,000 confirmed cases of the novel coronavirus worldwide, and 910 deaths, according to The World Health Organizations latest numbers.

(The institute) has been designed to look after major outbreaks in the world like this, and I just want you to know that were responding to this threat, said Tyrrell.

lijohnson@postmedia.com

twitter.com/reportrix

Go here to see the original:
'We're responding to this threat': University of Alberta works to help stop novel coronavirus - Edmonton Journal

Detection of Chromosomal and Plasmid-Mediated Quinolone Resistance Amo | IDR – Dove Medical Press

Noura E Esmaeel, 1 Marian A Gerges, 1 Thoraya A Hosny, 2 Ahmed R Ali, 3 Manar G Gebriel 1

1Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 2Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt; 3Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Correspondence: Marian A GergesMedical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, 44519, EgyptTel +20 1003819530Email maromicro2006@yahoo.com

Introduction: Resistance to fluoroquinolones (FQ) in uropathogenic Escherichia coli (UPEC) has emerged as a growing problem. Chromosomal mutations and plasmid-mediated quinolone resistance (PMQR) determinants have been implicated. Data concerning the prevalence of these determinants in UPEC in our hospital are quite limited.Purpose: To investigate the occurrence and genetic determinants of FQ resistance in UPEC isolated from urinary tract infection (UTI) cases in Zagazig University Hospitals.Patients and Methods: Following their isolation, the identification and susceptibility of UPEC isolates were performed by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometer (MALDI-TOF MS). FQ resistance was detected by the disc diffusion method. Ciprofloxacin minimal inhibitory concentration (MIC) was determined using E-test. Chromosomal mutations in the gyrA gene were detected using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and for detection of PMQR, a couple of multiplex PCR reactions were used.Results: Among a total of 192 UPEC isolates, 46.9% (n=90) were FQ resistant. More than half of the isolates (57.8%) exhibited high-level ciprofloxacin resistance (MIC > 32 g/mL). Mutations in gyrA were detected in 76.7% of isolates, with 34.4% having mutations at more than one site. PMQR determinants were detected in 80.1% of UPEC isolates, with aac(6)-Ib-cr gene being the most frequent found in 61.1% of isolates.Conclusion: There is a high prevalence of both gyrA mutations and PMQR determinants among UPEC isolates in our hospital which contribute to high-level ciprofloxacin resistance, a finding that may require the revision of the antibiotics used for empirical treatment of UTI.

Keywords: gyrA mutations, qnr determinants, uropathogenic E. coli, ciprofloxacin resistance

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Original post:
Detection of Chromosomal and Plasmid-Mediated Quinolone Resistance Amo | IDR - Dove Medical Press

Assistant/Associate, Department of Medical Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 195856 – Times Higher Education…

Job Description

The Department of Medical Microbiology & Immunology, College of Medicine and Health Sciences (CMHS), UAE University, seeks candidates for a faculty position at the rank of Assistant/Associate Professor in Microbiology. We are particularly looking for an innovative investigator who has an established, or a clear potential to establish an independent research program in host-parasite interactions at the cellular and molecular level. Preference will be given to candidates with a strong background in computational and systems biology, genomics or bioinformatics. The College of Medicine operates an internationally recognized, integrated, problem/team-based learning curriculum and provides excellent research facilities. English is the language of instruction. Current research in the department focuses on cancer immunology, autoimmune diseases, antibiotic resistance, host-pathogen interactions, retroviral RNA packaging, dimerization and gene expression, EBV and its role in the pathogenesis of human diseases, and public health.

Minimum Qualification

The successful candidate must have a PhD or MD/PhD from an accredited institution.

Preferred Qualification

As above

Expected Skills/Rank/Experience

It is expected that the successful candidate will also have experience in teaching medical students, and postgraduate students. Importantly, candidates must demonstrate the potential to establish an independent and sustained research program in their area of expertise and be able to obtain peer-reviewed internal and external funding. International collaboration is encouraged.

Special Instructions to Applicant

Attach CV and publication list, names & contact information of 3 referees, and a cover letter describing research and teaching experience.

Division College of Medicine&Health Sciences

Department Microbiology - (CMHS)

Job Close Date open until filled

Job Category Academic - Faculty

Salary 28000-35000 UAE Dirhams per month, based on experience

View post:
Assistant/Associate, Department of Medical Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 195856 - Times Higher Education...

This Colorado College Will Start Offering A Cannabis Major In The Fall – KFSM 5Newsonline

(CNN) Students on Colorado State Universitys Pueblo campus will have the option to study cannabis beginning this fall.

State officials on Friday approved a bachelors of science degree program in Cannabis Biology and Chemistry,according to the Colorado Department of Higher Education, which said it was one of the first such programs in the country.

The new major is a pro-active response to a rapidly changing national scene regarding the cannabis plant, a proposal for the program by CSU-Pueblo officials says, citing shifting attitudes toward cannabis and its legalization for recreational use in numerous states, including Colorado.

The program will be part of CSU-Pueblos department of chemistry and consist mainly of chemistry and biology coursework with some classes in math and physics, the proposal says.

Students could choose one of two tracks either a natural products track focused on biology, or an analytical track that focuses on chemistry.

Graduates could begin careers either in the cannabis and hemp industries or in the government.But they could also be competitive in a wide variety of businesses outside of the cannabis industry, it said, such as agriculture, food science, biochemistry and environmental sciences.

Educating students who are capable of understanding cannabis science is required for the industry in all its aspects to be effective and safe for the consumer, it said.

Between 2014 and June 2019, marijuana sales in Colorado exceeded $6.56 billion, according to the states Department of Revenue. With taxes, license and fee revenue, the states revenue reached more than $1 billion.

CSU-Pueblo anticipates a strong demand for the program, its proposal said, and believe as many 60 students could be enrolled in the major after four years.

The Colorado Department of Higher Education believes it could be the first of several cannabis-focused degrees that pop up at Colorado colleges in the near future.

CSU-Pueblos program will not be the first of its kind. Its proposal cited Northern Michigan Universitys bachelor program in medicinal plant chemistry that it said was primarily tailored to those wanting to enter the cannabis field.

CNN has reached out to CSU-Pueblo for comment.

See the original post here:
This Colorado College Will Start Offering A Cannabis Major In The Fall - KFSM 5Newsonline

Circulating Biomarkers of Handgrip Strength and Lung Function in Chron | COPD – Dove Medical Press

Rizwan Qaisar,1 Asima Karim,1,2 Tahir Muhammad3

1Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; 2University of Health Sciences, Lahore, Pakistan; 3Department of Biochemistry, Gomal Medical College, Gomal University, Dera Ismail Khan, Pakistan

Correspondence: Rizwan QaisarDepartment of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab EmiratesTel +971 6 505 7254Email rqaisar@sharjah.ac.ae

Purpose: COPD is a multisystem disease and there is a need for clinical serum markers that can assess the decline in lung and muscle function in COPD. The goal of this study was to evaluate the potential association of serum club-cell protein 16 (CC16), -1 acid glycoprotein (AGP) and total sialic acid (TSA) with spirometry, hand-grip strength and quality of life to assess important disease outcomes.Methods: This is a population-based cross-sectional study and data were collected from the patients at teaching hospitals of Gomal University and the University of Health Sciences in Pakistan. The study population included 1582 participants (Non-COPD; N = 788, COPD; N = 845) > 55 years of age from both sexes, with data from structural interviews, clinical examinations, laboratory investigations, spirometry and hand-grip strength measurements.Results: Serum TSA and CC16 were significant predictors of FEV1% (p < 0.05) and hand-grip strength in advanced stages of COPD (p < 0.05 each) in both sexes. Men had higher absolute and adjusted hand-grip strength than women in all groups (p < 0.05). Hand-grip strength was significantly associated with FEV1% in both genders (p < 0.05) with stronger effect in women (r2 = 0.075). Serum HDL-C was an independent predictor of hand-grip strength and FEV1% (p < 0.05) in both genders. Participants with extreme problem on EQ-5D parameters had more severe COPD and reduced hand-grip strength (all p values < 0.05).Conclusion: Taken together, these studies show that the serum expressions of TSA and CC16 have correlations with spirometry and muscle decline in COPD. Further studies should be conducted to establish their efficacy in monitoring disease progression in COPD.

Keywords: club cell protein 16, -1 acid glycoprotein, total sialic acid, EQ-5D, HDL-C

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Original post:
Circulating Biomarkers of Handgrip Strength and Lung Function in Chron | COPD - Dove Medical Press

Genetics Are Just One Part of How Children Develop

What determines how a child develops? While it is impossible to account for each and every influence that contributes to who a child eventually becomes, what researchers can do is look at some of the most apparent factors. These include things such as genetics, parenting, experiences, friends, family, education, and relationships. By understanding the role that these factors play, researchers are better able to identify how such influences contribute to development.

Think of these influences as building blocks. While most people tend to have the same basic building blocks, these components can be put together in an infinite number of ways. Consider your own overall personality. How much of who you are today was shaped by your genetic background, and how much is a result of your lifetime of experiences?

This question has puzzled philosophers, psychologists, and educators for hundreds of years and is frequently referred to as the nature versus nurture debate. Are we the result of nature (our genetic background) or nurture (our environment)? Today, most researchers agree that child development involves a complex interaction of both nature and nurture.

While some aspects of development may be strongly influenced by biology, environmental influences may also play a role. For example, the timing of when the onset of puberty occurs is largely the results of heredity, but environmental factors such as nutrition can also have an effect.

From the earliest moments of life, the interaction of heredity and the environment works to shape who children are and who they will become. While the genetic instructions a child inherits from his parents may set out a road map for development, the environment can impact how these directions are expressed, shaped or event silenced. The complex interaction of nature and nurture does not just occur at certain moments or at certain periods of time; it is persistent and lifelong.

In this article, we'll take a closer look at how biological influences help shape child development. We'll learn more about how our experiences interact with genetics and learn about some of the genetic disorders that can have an impact on child psychology and development.

At its very beginning, the development of a child starts when the male reproductive cell, or sperm, penetrates the protective outer membrane of the female reproductive cell, or ovum. The sperm and ovum each contain chromosomes that act as a blueprint for human life.

The genes contained in these chromosomes are made up of a chemical structure known as DNA (deoxyribonucleic acid) that contains the genetic code, or instructions, that make up all life. Except for the sperm and ova, all cells in the body contain 46 chromosomes. As you might guess, the sperm and ova each contain only contain 23 chromosomes. This ensures that when the two cells meet, the resulting new organism has the correct 46 chromosomes.

So how exactly do the genetic instructions passed down from both parents influence how a child develops and the traits they will have? In order to fully understand this, it is important to first distinguish between a child's genetic inheritance and the actual expression of those genes.

A genotype refers to all of the genes that a person has inherited. A phenotype is how these genes are actually expressed. The phenotype can include physical traits, such as height and color or the eyes, as well as nonphysical traits such as shyness and extroversion.

While your genotype may represent a blueprint for how children grow up, the way that these building blocks are put together determines how these genes will be expressed. Think of it as a bit like building a house. The same blueprint can result in a range of different homes that look quite similar but have important differences based on the material and color choices used during construction.

Whether or not a gene is expressed depends on two different things: the interaction of the gene with other genes and the continual interaction between the genotype and the environment.

Genetic instructions are not infallible and can go off track at times. Sometimes when a sperm or ovum is formed, the number of chromosomes may divide unevenly, causing the organism to have more or less than the normal 23 chromosomes. When one of these abnormal cells joins with a normal cell, the resulting zygote will have an uneven number of chromosomes.

Researchers suggest that as many as half of all zygotes that form have more or less than 23 chromosomes, but most of these are spontaneously aborted and never develop into a full-term baby.

In some cases, babies are born with an abnormal number of chromosomes. In every case, the result is some type of syndrome with a set of distinguishing characteristics.

The vast majority of newborns, both boys and girls, have at least one X chromosome. In some cases, about 1 in every 500 births, children are born with either a missing X chromosome or an additional sex chromosome. Klinefelter syndrome, Fragile X syndrome,and Turner syndrome are all examples of abnormalities involving the sex chromosomes.

Kleinfelter's syndrome is caused by an extra X chromosome and is characterized by a lack of development of the secondary sex characteristics and as well as learning disabilities.

Fragile X syndrome is caused when part of the X chromosome is attached to the other chromosomes by such a thin string of molecules that it seems in danger of breaking off. It can affect both males and females, but the impact can vary. Some with Fragile X show few if any signs, while others develop mild to severe mental retardation.

Turner syndrome occurs when only one sex chromosome (the X chromosome) is present. It affects only females and can result in short stature, a "webbed" neck and a lack of secondary sex characteristics. Psychological impairments associated with Turner syndrome include learning disabilities and difficulty recognizing emotions conveyed through facial expressions.

The most common type of chromosomal disorder is known as trisomy 21, or Down syndrome. In this case, the child has three chromosomes at the site of the 21st chromosomes instead of the normal two.

Down syndrome is characterized by facial characteristics including a round face, slanted eyes, and a thick tongue. Individuals with Down syndrome may also face other physical problems including heart defects and hearing problems. Nearly all individuals with Down syndrome experience some type of intellectual impairment, but the exact severity can vary dramatically.

Clearly, genetics have an enormous influence on how a child develops. However, it is important to remember that genetics is just one piece of the intricate puzzle that makes up a child's life. Environmental variables including parenting, culture, education, and social relationships also play a vital role.

Original post:
Genetics Are Just One Part of How Children Develop